Abstract

Quinoline core has been shown to possess a promising role in the development of anticancer agents. However, the correlation between its broad spectrum of bioactivity and the underlying mechanism of actions is poorly understood. The present study, with the use of bioinformatics approaches, reported a series of designed molecules which integrated quinoline core and sulfonyl moiety, with the objective of evaluating the substituent and linker effects on anticancer activities and associated mechanistic targets. We identified potent compounds (1h, 2h, 5 and 8) exhibiting significant anticancer effects towards liver cancer cells (Hep3B) with the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) relative values of cytotoxicity below 0.40, a value in the range of doxorubicin positive control with the value of 0.12. Bulky substituents and the presence of bromine atom, as well as the presence of sulfonamide linkage, are likely the favorable structural components for molecules exerting a strong anticancer effect. To the best of our knowledge, our findings obtained from chemical synthesis, in vitro cytotoxicity, bioinformatics-based molecular docking analysis (similarity ensemble approach, SEA),and electrophoretic mobility shift assay provided the first evidence in correlation to the anticancer activities of the selected compound 5 with the modulation on the binding of transcription factor NF-κB to its target DNA. Accordingly, compound 5 represented a lead structure for the development of quinoline-based NF-κB inhibitors and this work added novel information on the understanding of the mechanism of action for bioactive sulfonyl-containing quinoline compounds against hepatocellular carcinoma.

Details

Title
Targeting DNA Binding for NF-κB as an Anticancer Approach in Hepatocellular Carcinoma
Author
Chung, Po Yee 1   VIAFID ORCID Logo  ; Lam, Pik Ling 1 ; Zhou, Yuanyuan 1 ; Gasparello, Jessica 2   VIAFID ORCID Logo  ; Finotti, Alessia 2   VIAFID ORCID Logo  ; Chilin, Adriana 3 ; Marzaro, Giovanni 3   VIAFID ORCID Logo  ; Gambari, Roberto 2 ; Bian, Zhaoxiang 4 ; Kwok, Wai Ming 1 ; Wai Yeung Wong 1 ; Wang, Xi 1 ; Alfred King-yin Lam 5   VIAFID ORCID Logo  ; Albert Sun-chi Chan 6 ; Li, Xingshu 6 ; Jessica Yuen Wuen Ma 7 ; Chui, Chung Hin 1 ; Lam, Kim Hung 1 ; Johnny Cheuk On Tang 1 

 State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China 
 Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy 
 Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35122 Padova, Italy 
 Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China 
 Griffith Medical School, Griffith University, Gold Coast, QLD 4222, Australia 
 School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China 
 School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China 
First page
177
Publication year
2018
Publication date
2018
Publisher
MDPI AG
e-ISSN
20734409
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2582793036
Copyright
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.